Ocular Therapeutix Management

Dr. Pravin U. Dugel, M. D. has been Executive Chairman of Ocular Therapeutix, Inc. since February 2024 and also serves as its Chief Executive Officer and President since April 15, 2024. He served as Presid...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Donald Notman	Chief Financial Officer	6.7yrs	US$1.34m	0.050% $ 440.8k
Jeffrey Heier	Chief Scientific Officer	less than a year	US$329.90k	0.031% $ 270.4k
Rabia Ozden	Chief Medical Officer	3.3yrs	US$1.48m	0.019% $ 167.8k
Pravin Dugel	Executive Chairman	less than a year	no data	no data
Karen-Leigh Edwards	Chief Operations Officer	less than a year	no data	no data
Peter Jarrett	Chief Technology Officer	no data	no data	no data
William Slattery	Vice President of Investor Relations	no data	no data	no data
Philip Strassburger	General Counsel	3.7yrs	US$2.41m	no data
William Ransone	Vice President of Global Sales & Marketing	no data	no data	no data
Tracy Smith	Vice President of Human Resources	3.7yrs	no data	no data
Steve Meyers	Chief Commercial Officer	1.3yrs	no data	no data
Peter Kaiser	Chief Development Officer	less than a year	no data	no data

1.3yrs

Average Tenure

62yo

Average Age

Experienced Management: OCUL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Pravin Dugel	Executive Chairman	less than a year	no data	no data
Charles Warden	Lead Independent Director	16.3yrs	US$303.61k	0.031% $ 273.3k
Merilee Raines	Independent Director	2.7yrs	US$263.61k	0.0058% $ 50.4k
Richard Lindstrom	Independent Director	11.5yrs	US$261.11k	0.090% $ 782.3k
Adrienne Graves	Independent Director	less than a year	US$397.89k	no data
Leslie Williams	Independent Director	5.2yrs	US$261.11k	0.0087% $ 75.7k
Seung Hong	Independent Director	4.9yrs	US$248.61k	0.0058% $ 50.4k

4.9yrs

Average Tenure

65yo

Average Age

Experienced Board: OCUL's board of directors are considered experienced (4.9 years average tenure).

Ocular Therapeutix Management

Management criteria checks 1/4

Key information

Recent management updates

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Executive Changes

Ocular Therapeutix, Inc. Announces Management Changes

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

President notifies of intention to sell stock

Recent updates

Consensus EPS estimates fall by 23%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. to Report Q1, 2024 Results on May 07, 2024

Ocular Therapeutix, Inc., Annual General Meeting, Jun 12, 2024

Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Ocular Therapeutix, Inc. Announces CEO Changes

Ocular Therapeutix, Inc. Announces Executive Changes

Consensus EPS estimates fall by 29%

Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Ocular Therapeutics' Impressive Surge: A Strategic Insight

Consensus EPS estimates upgraded to US$0.67 loss, revenue downgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocular Therapeutix, Inc. to Report Q4, 2023 Results on Mar 11, 2024

Ocular Therapeutix, Inc. Announces Management Changes

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA

Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer

Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement

President notifies of intention to sell stock

President recently sold US$91k worth of stock

President notifies of intention to sell stock

Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment (Spa) for Pivotal Clinical Trial of Axpaxli in Wet AMD

Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD

Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking

Price target decreased by 9.7% to US$11.86

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

Ocular Therapeutix, Inc. has completed a Follow-on Equity Offering in the amount of $100.1 million.

New minor risk - Profitability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Full Year 2023

Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

AffaMed Therapeutics Announces Positive Top-Line Results from Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Patients after Cataract Surgery

New minor risk - Share price stability

Ocular Therapeutix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?

Ocular Therapeutix, Inc. Announces Initiation of Its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

Ocular Therapeutix, Inc. Submits Request for Special Protocol Assessment to the U.S. Food and Drug Administration

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ocular Therapeutix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Ocular Therapeutix™ Announces Appointment of Adrienne L. Graves as New Board Member

Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?

New minor risk - Share price stability

Ocular Therapeutix, Inc. Completes Enrollment of the Helios Clinical Trial of OTX-TKI for the Treatment of Diabetic Retinopathy

Ocular Therapeutix, Inc. Present 12-Month Top-Line Data from U.S.-Based Phase 1 Clinical Trial of OTX-TKI

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 7.8% to US$12.63

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ocular Therapeutix™ Announces Interim 10-Month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?

President notifies of intention to sell stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be

Consensus revenue estimates fall by 13%

Insufficient new directors

Price target decreased to US$13.29

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ocular Therapeutix, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Ocular Therapeutix, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Ocular Therapeutix, Inc. Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Price target increased to US$15.92

Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event

Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Ocular Therapeutix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

Ocular Therapeutix, Inc. Announces Executive Changes